Jim Shin

could you just give us an update on Yeztugo's buy-and-bill and white bagging mix

there were some price benefits to Descovy. But is there any read-through or implications to LEN's launch

can you share any similarities or differences you foresee with what you went through previously during the Part D senior savings model for insulins $35 co-pay rollout

does that suggest greater GTM pressure than what you would normally have with rebates? Does this make clinical profiles more relevant to form like positioning or access

is the mid to high single-digit price headwind still intact following the CVS formulary decision on Zepbound and also given the movement in FX?

can you go over how this titration schedule may impact the Phase II weight loss, A1c and safety results published in Lancet and New England Journal?

On Cadence's ACA presentation, can you help level state what we should and should not expect to learn

was Merck notified of Sino Biopharm's interest in LaNova? And does that have any bearing on Merck's commitment to 2010

is there a need for more or room for more US CapEx? And is it pending US tax reform

there is an upcoming February 2025 ACIP meeting, and the agenda suggests there's some follow-up on last October